4.3 Article

Incidence and Predictors of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Implantation: Analysis from the German Transcatheter Aortic Valve Interventions Registry

Journal

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
Volume 82, Issue 4, Pages E569-E577

Publisher

WILEY
DOI: 10.1002/ccd.24915

Keywords

transcatheter aortic valve implantation; permanent pacemaker implantation; predictors; incidence

Funding

  1. Biosense Webster
  2. Stereotaxis
  3. Medtronic
  4. Access Closure
  5. AGA
  6. Angiomed
  7. Ardian
  8. Arstasis
  9. Atritech
  10. Atrium
  11. Avinger
  12. Bard
  13. Boston Scientific
  14. Bridgepoint
  15. CardioKinetix
  16. CardioMEMS
  17. Coherex
  18. Contego
  19. CSI
  20. EndoCross
  21. EndoTex
  22. Epitek
  23. Evalve
  24. ev3
  25. FlowCardia
  26. Gore
  27. Guidant
  28. Lumen Biomedical
  29. HLT
  30. Kensey Nash
  31. Kyoto Medical
  32. Lifetech
  33. Lutonix
  34. Medinol
  35. NDC
  36. NMT
  37. OAS
  38. Occlutech
  39. Osprey
  40. Ovalis
  41. Pathway
  42. PendraCare
  43. Percardia
  44. pfm Medical
  45. Recor
  46. Rox Medical
  47. Sadra
  48. Sorin
  49. Spectranetics
  50. SquareOne
  51. Trireme
  52. Trivascular
  53. Viacor
  54. Velocimed
  55. Veryan

Ask authors/readers for more resources

ObjectivesTo determine predictors of permanent pacemaker (PPM) implantation up to 30 days after transcatheter aortic valve implantation (TAVI) in a prospective multicenter registry. BackgroundConduction disorders requiring PPM implantation are one of the most common complications seen after TAVI. Knowledge about possible predictors may help to decrease the rate of PPM implantations. MethodsIn total, 1347 consecutive patients who underwent TAVI in 22 centers were prospectively enrolled in the German transcatheter aortic valve interventions registry. Both Medtronic CoreValve and Edwards Sapien valves were implanted. Patients with preprocedurally implanted PPM or implantable cardioverter defibrillator were excluded from the analysis (n=199). Regression analysis of baseline and procedure characteristics of the remaining 1,147 patients was performed. ResultsProcedural success was achieved in 97.4% of the cases. The rate for PPM after TAVI was 33.7%. The absence of prior valve surgery, the use of Medtronic CoreValve prosthesis and the presence of a porcelain aorta were identified as independent predictors for PPM after TAVI. Mortality at 30 days did not differ between patients with or without PPM necessity (6.0% vs. 8.1%, respectively; HR 0.72; CI (0.45-1.16); P=0.17). ConclusionsPPM is a common postprocedure requirement after TAVI. The absence of prior valve surgery, the implantation of Medtronic CoreValve prosthesis, and the presence of a porcelain aorta were independently associated with PPM after TAVI. (c) 2013 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available